Loading clinical trials...

Travoprost Five Day Posology Study | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Travoprost Five Day Posology Study

NCT01114893•Alcon Research

Summary

The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. either sex and any race/ethnicity, ≥18 years old
•2. diagnosed with open-angle glaucoma, and/or ocular hypertension
•3. meets the following IOP entry criteria:
•* Mean IOP ≥ 24 millimeters mercury (mmHg) in at least 1 eye, with the same eye qualifying at 8 AM on both the Eligibility Visit (Day 0) and Day 1
•* Mean IOP ≤ 36 mmHg in both eyes at 8 AM and 8 PM at the Eligibility Visit (Day 0), and at 8 AM on Day 1
•4. satisfies all informed consent requirements; able to read, sign and date the informed consent

Exclusion Criteria

•1. females of childbearing potential not meeting protocol conditions
•2. angle grade less than Grade 2 in either eye
•3. cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye
•4. severe central visual field loss in either eye
•5. any abnormality preventing reliable applanation tonometry in either eye
•6. hypersensitivity to prostaglandin analogues or to any component of the study medication

Locations (1)

Contact Alcon Call Center For Trial Locations

Fort Worth, Texas, United States

Key Dates

Start Date

April 1, 2010

Primary Completion Date

May 1, 2010

Last Updated

June 23, 2011

Enrollment

ACTUAL participants

Conditions

Open-angle Glaucoma (OAG)Ocular Hypertension

Interventions

Travoprost 0.004%

DRUG

Travoprost Vehicle

DRUG

Travoprost (Groups A, B and C)

DRUG

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 23, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Travoprost Five Day Posology Study

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring